Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatmentinsights.

Abstract

Tebentafusp, recently approved by the FDA as an immunotherapy agent, has shown great promise in improving outcomes for metastatic uveal melanoma. In this case series, we present six patients treated with tebentafusp at our institution, focusing on the associated cutaneous adverse reactions and their management. A better understanding of the cutaneous adverse reactions associated with tebentafusp is important because, given its promising treatment outcomes, the use of tebentafusp will likely become more widespread. This study highlights the range of possible outcomes and effective treatment regimens for mild-to-severe cutaneous reactions, ensuring that patients can continue tebentafusp treatment without interruption in most cases.